StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $23.88 | $25.51 | +6.83% | 3.3M |
| 05-14 | $23.53 | $24.87 | +5.69% | 5.4M |
| 05-15 | $23.10 | $20.56 | -11.00% | 6.9M |
| 05-18 | $20.95 | $20.63 | -1.53% | 3.3M |
| 05-19 | $20.40 | $20.30 | -0.49% | 1.9M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $62.38M | $62.38M | $8.57M |
Operating Income | $-48.77M | $-111.29M | $-69.42M | $-83.50M |
Net Income | $-45.51M | $-101.59M | $-62.84M | $-38.85M |
EPS (Diluted) | $-0.32 | $-0.87 | $-0.57 | $-0.71 |
Total Assets | $435.79M | $398.69M | $210.14M | $237.89M |
Total Liabilities | $44.29M | $52.51M | $50.10M | $102.94M |
Cash & Equivalents | $157.83M | $112.28M | $58.34M | $39.27M |
Free Cash Flow OCF − CapEx | $-44.36M | $-139.93M | $-109.99M | $-78.89M |
Shares Outstanding | 144.16M | 135.94M | 111.57M | 110.87M |
No sell-side coverage available for TNGX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Fundamentals not available for TNGX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.